Home  |  Contact

Cellosaurus LAPC-4-EnzR (CVCL_RA56)

[Text version]

Cell line name LAPC-4-EnzR
Accession CVCL_RA56
Resource Identification Initiative To cite this cell line use: LAPC-4-EnzR (RRID:CVCL_RA56)
Comments Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; MDV-3100).
Omics: Transcriptome analysis.
Sequence variations
  • Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_4744 (LAPC-4)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
Publications

PubMed=27036029; DOI=10.18632/oncotarget.8456
Kregel S., Chen J.L., Tom W., Krishnan V., Kach J., Brechka H., Fessenden T.B., Isikbay M., Paner G.P., Szmulewitz R.Z., Vander Griend D.J.
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Oncotarget 7:26259-26274(2016)

Cross-references
Encyclopedic resources Wikidata; Q54901926
Gene expression databases GEO; GSM2069514
GEO; GSM2069515
GEO; GSM2069516
GEO; GSM2069517
Entry history
Entry creation05-Mar-2018
Last entry update20-May-2021
Version number5